San Francisco startup Composition Therapeutics can also be engaged on an oral, when-everyday GLP-1 drug called GSBR-1290—the drug surpassed Wall Street’s expectations in June each time a mid-stage examine showed typical weight loss of around 6% and it strategies to start A further mid-phase trial toward the end of the year—that founder and CE